Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Payables: 2019-2024

Historic Payables for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $4.4 million.

  • 4D Molecular Therapeutics' Payables rose 134.71% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 71.08%. This contributed to the annual value of $4.4 million for FY2024, which is 24.78% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Payables stood at $4.4 million for FY2024, which was up 24.78% from $3.5 million recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Payables peaked at $4.8 million during FY2021, and registered a low of $1.8 million during FY2020.
  • For the 3-year period, 4D Molecular Therapeutics' Payables averaged around $3.7 million, with its median value being $3.5 million (2023).
  • Its Payables has fluctuated over the past 5 years, first spiked by 166.59% in 2021, then crashed by 30.27% in 2022.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Payables stood at $1.8 million in 2020, then surged by 166.59% to $4.8 million in 2021, then crashed by 30.27% to $3.3 million in 2022, then increased by 5.81% to $3.5 million in 2023, then rose by 24.78% to $4.4 million in 2024.